We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+49.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.26B
AUM Growth
+$210M
Cap. Flow
-$90.5M
Cap. Flow %
-7.19%
Top 10 Hldgs %
54.98%
Holding
68
New
14
Increased
7
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$52.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$32.1M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$28.5M
5
INCY icon
Incyte
INCY
+$24.9M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$56.1M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.6M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$25.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.1M
5
BKD icon
Brookdale Senior Living
BKD
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.15%
2 Communication Services 1.37%
3 Consumer Staples 0.51%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$112M 8.94%
16,658,072
-2,492,578
-13% -$9.64M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$96.2M 7.65%
1,781,470
+399,993
+29% +$19M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$94.4M 7.51%
12,751,536
+1,645,090
+15% +$11.1M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$73.9M 5.88%
2,049,985
-1,047,865
-34% -$22.5M
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$72.5M 5.76%
+545,922
New +$52.2M
INCY icon
6
Incyte
INCY
$23.1B
$56.4M 4.48%
597,638
+295,331
+98% +$24.9M
PEN icon
7
Penumbra
PEN
$12.5B
$51.1M 4.07%
672,918
-190,663
-22% -$13.2M
MOH icon
8
Molina Healthcare
MOH
$12B
$45.4M 3.61%
778,160
-67,200
-8% -$3.7M
ELGX
9
DELISTED
Endologix Inc
ELGX
$44.6M 3.54%
348,064
-48,211
-12% -$6.17M
PBYI icon
10
Puma Biotechnology
PBYI
$422M
$44.4M 3.53%
+662,286
New +$33.5M
ATRA icon
11
Atara Biotherapeutics
ATRA
$74.7M
$43.2M 3.44%
80,865
-15,494
-16% -$8.41M
PRTA icon
12
Prothena Corp
PRTA
$454M
$42.1M 3.35%
701,659
+214,253
+44% +$11.5M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.78B
$39.3M 3.13%
+640,400
New +$19.4M
AGIO icon
14
Agios Pharmaceuticals
AGIO
$2.38B
$39M 3.1%
+737,900
New +$32.1M
CNC icon
15
Centene
CNC
$32.5B
$31.1M 2.47%
928,154
+357,868
+63% +$12.4M
ARIA
16
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$29.3M 2.33%
+2,138,471
New +$21.5M
BSX icon
17
Boston Scientific
BSX
$65.1B
$25.5M 2.03%
1,072,638
-157,682
-13% -$3.76M
NSTG
18
DELISTED
NanoString Technologies, Inc.
NSTG
$24.7M 1.97%
1,237,435
-711,750
-37% -$11.3M
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$23.7M 1.89%
227,267
-171,104
-43% -$15.5M
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$23.3M 1.85%
+505,154
New +$28.5M
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$23M 1.83%
+702,539
New +$21.4M
WVE icon
22
Wave Life Sciences
WVE
$1.1B
$22.8M 1.81%
701,822
-393,651
-36% -$9.3M
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$20.8M 1.66%
916,927
-549,610
-37% -$12.9M
OXFD
24
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$18M 1.43%
1,431,119
+3,025
+0.2% +$30.4K
CMRX
25
DELISTED
Chimerix, Inc.
CMRX
$17.8M 1.42%
3,214,946
-73,430
-2% -$336K
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2016 Portfolio in Review

As of Q3 2016, Redmile Group held 68 positions worth $1.26B, up 20% from $1.05B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $90.5M in Q3 2016, closing 17 positions and reducing 27 holdings. Its most notable exit was MEDIVATION, INC., an estimated $56.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 73% a quarter earlier, followed by Communication Services and Consumer Staples.

Against the trend, Redmile Group opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $72.5M.

  • Redmile Group's largest Q3 2016 buy was GW Pharmaceuticals Plc American Depositary Shares: 545,922 shares worth $72.5M.
  • Redmile Group added most to Incyte in Q3 2016, an estimated $24.9M increase.
  • Redmile Group's biggest Q3 2016 reduction was Intra-Cellular Therapies Inc., cutting an estimated $25.7M.
  • Redmile Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $56.1M.
  • Redmile Group's ten largest holdings make up 55% of its $1.26B portfolio in Q3 2016.
  • Redmile Group opened 14 new positions and closed 17 in Q3 2016.
  • Redmile Group's portfolio value rose 20% quarter-over-quarter to $1.26B.

Based on Redmile Group's 13F filing for Q3 2016, filed 15 Nov 2016.